Lundbeck carries on Rexulti study after new analysis

After having received a new interim analysis, Lundbeck and its partner Otsuka have decided to keep going with a phase III study with the drug Rexulti for treating Alzheimer's symptoms.
Photo: Jens Dresling
Photo: Jens Dresling
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Danish pharmaceutical company Lundbeck and its partner Japanese pharmaceutical firm Otsuka have long been anticipating the results of their phase III trial with Rexulti, or brexpiprazole, for treating agitation in patients suffering from the dementia disease Alzheimer's.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading